CareDx Introduces New Patient-Centric Medication Management Capabilities in AlloCare Mobile Health App – BioSpace | Hot Mobile Press

MedActionPlan PRO integration facilitates patient-physician interaction to improve medication adherence

BRISBANE, Calif.–(BUSINESS WIRE)–CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development and commercialization of clinically differentiated, high quality healthcare solutions for transplant patients and caregivers – today announced that its AlloCare® mobile health app offers enhanced capabilities for medication compliance and patient-provider communication resulting from the successful integration of MedActionPlan®, an acquisition made last year.

MedActionPlan PRO is a medication management and adherence platform designed to simplify post-transplant medication. It is used by more than 140 transplant centers to simplify post-transplant medication. With the integration of MedActionPlan PRO into the AlloCare app, participating transplant centers can now deliver personalized education, medication plan details and reminders directly to their patients’ smartphones. Patients are able to better control their health and medication intake.

“CareDx’s strategy of providing patient-centric digital health solutions to improve transplantation has come to fruition with the seamless integration of MedActionPlan PRO into our AlloCare app,” said Reg Seeto, CEO and President of CareDx. “We are incredibly proud to expand the medication management capabilities of our AlloCare app to help thousands of patients and their physicians collaborate to successfully manage complex medication regimens for optimal graft health and longevity.”

Downloaded over 50,000 times, the popular AlloCare mobile app helps patients navigate the pre-transplant referral and waitlisting process, and post-transplant helps them track their personal health information and test results, manage their complex medication schedules, and engage with to connect other users who had a transplant.

“As an early adopter of MedActionPlan PRO, I have been a strong advocate of its use for over two decades. I am delighted that CareDx has integrated this leading medication compliance platform into its AlloCare app, as far too many patients experience complications and graft failure due to errors in medication dosing and timing,” said Pamela Maxwell, PharmD, BCPS, Executive Director of Clinical Pharmacy Services at University Health in San Antonio, Texas.

Kiran Dhanireddy, MD, FACS, Vice President of Transplant Institute and Surgical Director of Liver Transplantation at Tampa General Hospital added, “The integration of the MedActionPlan PRO platform directly into the AlloCare app is an exciting development that participating centers are helping to make will be able to easily send medication information and notifications directly to a patient’s smartphone to encourage medication adherence and positive health outcomes.”

Medication non-compliance is one of the leading causes of organ transplant loss.1-3 For kidney transplants, research shows that up to fifty-two percent of patients do not take their medications as prescribed4 and that up to sixty percent of non-adherence is unintentional and may be the result of forgetting to take medication or a lack of awareness of the importance of strictly adhering to the medication schedule.5 Medication regimens for organ transplant patients are incredibly complex. Adding to the complexity of transplant medication are regular dose changes, on and off days, and weaning schedules.

More information about MedActionPlan PRO can be found here.

About CareDx – The Transplant Company

CareDx, Inc., headquartered in Brisbane, California, is a leading precision medicine solutions company focused on the discovery, development and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. CareDx provides testing services, products and digital healthcare solutions along the pre- and post-transplant patient journey and is the leading provider of genomic information for transplant patients. For more information, please visit: www.CareDx.com.

Forward-Looking Statements

This press release contains forward-looking statements regarding CareDx, Inc., including statements regarding the potential benefits and results to be achieved with AlloCare® and the integration of MedActionPlan PRO with the AlloCare mobile app (the “Integration”). These forward-looking statements are based on information currently available to CareDx and its current expectations, speak only as of the date of this release, and are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including such risks to CareDx does not recognize the expected benefits of AlloCare or the integration; general economic and market factors; and other risks discussed in CareDx’s filings with the SEC, including its annual report on Form 10-K for the fiscal year ended December 31, 2021, filed by CareDx with the SEC on February 24, 2022, des Quarterly Report on Form 10-Q for the first quarter of 2022 ended March 31, 2022 filed by CareDx with the SEC on May 5, 2022 and other reports filed by CareDx with the SEC. Any of these could cause CareDx’s actual results, performance or achievements to differ materially and adversely from those anticipated or implied by CareDx’s forward-looking statements. CareDx expressly disclaims any obligation to update or revise any such forward-looking statements, except as required by law.

References:

  1. Gandolfini I, Palmisano A, Fiaccadori E, et al. Recognize, prevent and treat non-compliance with immunosuppression after kidney transplantation. Clinical Kidney Journal. 2022;15(7):1253-1274. https://doi.org/10.1093/ckj/sfac017
  2. Dobbels F, Geest SD, Cleemput JV, et al. Effect of late medication noncompliance on outcome after heart transplantation: A 5-year follow-up. The Journal of Heart and Lung Transplantation. 2004; 23(11): 1245-1251. https://doi.org/10.1016/j.healun.2003.09.016
  3. Bertram A, Fuge J, Suhling H, et al. Adherence is associated with a favorable outcome after lung transplantation. PLUS ONE. 2019:14(12):e0226167. https://doi.org/10.1371/journal.pone.0226167
  4. Hucker A, Bunn F, Carpenter L, et al. Non-compliance with immunosuppressive drugs after kidney transplantation: a protocol for a systematic review. BMJ open. 2017; 7(9):e015411. doi: 10.1136/bmjopen-2016-015411.
  5. Griva K, Davenport A, Harrison M et al. Non-adherence to immunosuppressive medication in renal transplant: intention vs. forgetfulness and clinical markers of medication use, Annals of behavioral medicine. 2012; 44 (1): 85-93, https://doi.org/10.1007/s12160-012-9359-4

Leave a Comment